ImmunoPrecise Antibodies/IPA

-0.85%
-
1D1W1MYTD1YMAX

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd. is a Canada-based full-service, therapeutic antibody discovery company. The Company offers species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program- platforms. It leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its technologies in bio platform-based antibody discovery. It offers a selection of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma licensing for research purposes. Its services include specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners. The Company offers support to its partners, including rapid multi-omic analysis, customized project design, target identification and preparation, an on-site vivarium, and others.

Ticker

IPA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jennifer Bath

Employees

85

Headquarters

Vancouver, Canada

IPA Metrics

BasicAdvanced
US$162M
Market cap
-
P/E ratio
-US$1.06
EPS
0.26
Beta
-
Dividend rate
US$162M
0.26067
US$8.81
US$4.52
15K
5.058
4.769
0.465
1.697
-31.67%
-37.57%
-34.53%
8.312
2.437
9.474
3.9%
-95.7%
21.02%

What the Analysts think about IPA

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
498.29% upside
High US$9.00
Low US$5.00
US$1.17
Current price
US$7.00
Average price target

IPA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 10%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-CA$0.21
-CA$0.14
-CA$0.10
-CA$0.11
-
Expected
-CA$0.17
-CA$0.21
-CA$0.13
-CA$0.10
-CA$0.12
Surprise
23.53%
-31.71%
-23.08%
10%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ImmunoPrecise Antibodies stock?

ImmunoPrecise Antibodies (IPA) has a market cap of $162M as of May 20, 2024.

What is the P/E ratio for ImmunoPrecise Antibodies stock?

The price to earnings (P/E) ratio for ImmunoPrecise Antibodies (IPA) stock is 0 as of May 20, 2024.

Does ImmunoPrecise Antibodies stock pay dividends?

No, ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next ImmunoPrecise Antibodies dividend payment date?

ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders.

What is the beta indicator for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies (IPA) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the ImmunoPrecise Antibodies stock price target?

The target price for ImmunoPrecise Antibodies (IPA) stock is $7, which is 498.29% above the current price of $1.17. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ImmunoPrecise Antibodies stock

Buy or sell ImmunoPrecise Antibodies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing